24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825
Fax: (361)578-5500

Child & Adolescent Development: Overview
Resources
Basic InformationMore InformationLatest News
Why Are Fewer U.S. Kids Going to Pediatricians?Severe Deprivation in Childhood Has Lasting Impact on Brain SizeHealth Tip: What Your Child Can do About BullyingWildfires Send Kids to ERs for Breathing ProblemsTV Can Be a Good Influence on Kids' Eating HabitsWould Tighter Swimming Rules at Public Beaches, Lakes and Rivers Save Lives?U.S. Doctors Often Test, Treat Kids UnnecessarilyHealth Tip: Safety Steps if Your Child is Home AloneHealth Tip: Help Your Child Safely Lose WeightAmericans Need to Tackle Youth Obesity: U.S. Task ForceGenes, Family Are Key Predictors of School SuccessKids' 'Microbiome' May Play Key Role in AsthmaA Puppy in Santa's Sack? Probably Not, Say ParentsMore Kids, Teens Landing in ERs After Opioid OverdosesGetting Active Helps Kids' Hearts, Even in the ObeseWhen Does Your Child's Flu Merit an ER Visit?Health Tip: Managing Hearing Loss in ChildrenHealth Tip: Is My Child Too Sick to Go to School?Differences Found in Brains of Kids Born to Depressed ParentsSecondhand Smoke Starts Kids on Path to Heart Disease: StudyHealth Tip: Choosing a PediatricianMany Kids Traveling Overseas Aren't Vaccinated Against MeaslesCould Obesity Alter a Child's Brain Structure?Dramatic Rise in Eye Injuries From BB and Paintball GunsTwo-Thirds of Child Abuse Survivors Do Well as AdultsAHA News: Serious Heart Defects Increase Heart Failure Risk in Early AdulthoodMore U.S. Kids Are Shunning Sweetened DrinksAs Disease Outbreaks Tied to 'Anti-Vaxxers' Rise, States Take Action'Don't Give Up:' Parents' Intuition Spots a Rare Illness Before Doctors DoFDA Approves First Contact Lens That Slows Myopia ProgressionStereotypes About Girls and Math Don't Add Up, Scans ShowStudies Confirm HPV Shot Is SafeThese Sports Are Most Likely to Send Young Americans to the ERNature Nurtures KidsClimate Change Will Hurt Kids Most, Report WarnsTough Childhoods Can Leave a Lifetime of Harm, Experts SayMany U.S. Parents Can't Find a Psychiatrist to Help Their ChildAnti-Vaxxers Find Ways Around States' 'Personal Exemption' BansMake a Plan for Gardening Next Spring With Your KidsCheck Those Halloween Treats So They're Safe to EatFast-Food Outlet in Neighborhood Could Mean Heavier Kids: StudyAntihistamines Linked to Delayed Care for Severe Allergic Reaction: StudyPain Twice as Common for Kids With Autism: StudyPediatricians' Group Calls for More Research on Artificial SweetenersExperts Support Weight-Loss Surgery for Very Obese KidsHalloween Can Be Frightful for Kids With Allergies, AsthmaLawn Mowers May Be Even More Dangerous for Rural KidsHow Young Is Too Young to Leave Kids Home Alone?Skiing, Snowboarding Injuries Most Severe Among Younger KidsKids' Trampoline Injuries Take Another Bounce Upwards
Questions and AnswersLinks
Related Topics

ADHD: Attention Deficit Hyperactivity Disorder
Childhood Mental Disorders and Illnesses
Child Development & Parenting: Infants (0-2)
Child Development & Parenting: Early (3-7)

FDA Expands Cystic Fibrosis Treatment Approval to Children Ages 6 to 12


HealthDay News
Updated: Jun 24th 2019

new article illustration

MONDAY, June 24, 2019 (HealthDay News) -- The indication for a cystic fibrosis treatment, Symdeko (tezacaftor/ivacaftor) tablets, has been expanded to treat children ages 6 years and older with cystic fibrosis and certain genetic mutations, the U.S. Food and Drug Administration announced today.

Symdeko is approved to treat patients with two copies of the F508del mutation, the most common type of mutation, and patients who have at least one of the mutations in the CFTR gene that is responsive to the active ingredients in Symdeko. The FDA approved Symdeko last year for treatment in children ages 12 years and older with the same genetic mutations. Dosage in children ages 6 to 12 years weighing less than 30 kg is one tablet of 50 mg tezacaftor and 75 mg ivacaftor in the morning and one tablet of 75 mg ivacaftor approximately 12 hours later. In patients aged 12 years and older or who weigh 30 kg or more, dosage is one tablet containing 100 mg tezacaftor and 150 mg ivacaftor and a tablet containing 150 mg ivacaftor 12 hours later.

Symdeko's approval was based on three phase 3, double-blind, placebo-controlled trials that showed improvements in lung function and a reduction in exacerbations. The expanded indication approval to children ages 6 to 12 years was based on data from patients aged 12 years and older and additional support from data on patients aged 6 to 12 years. Symdeko's safety in children ages 6 to 12 years was demonstrated in a 24-week, open-label study of 70 cystic fibrosis patients aged 6 to 12 years.

Symdeko's labeling indicates that it should always be taken with food containing fat and should never be combined with certain antibiotics, seizure medications, St. John's wort, or food containing grapefruit or Seville oranges. The prescribing information includes warnings of elevated transaminases and the risk for cataracts in children taking Symdeko and warns against taking Symdeko simultaneously with CYP3A inducers. The most commonly reported side effects were headache, nausea, sinus congestion, and dizziness.

Approval was granted to Vertex Pharmaceuticals.

More Information